Background ! According to the most recent estimates by the International Agency for Research on Cancer [12] colorectal cancer (CRC) is the most common cancer in Europe with 432 000 new cases in men and women reported annually. It is the second most common cause of cancer deaths in Europe with 212 000 deaths reported in 2008. Worldwide CRC ranks third in incidence and fourth in mortality with an estimated 1.2 million cases and 0.6 million deaths annually. The European Union (EU) recommends population-based screening for breast, cervical and colorectal cancer using evidence-based tests with quality assurance of the entire screening process including diagnosis and management of patients with screen-detected lesions [5] . The EU policy takes into account the principles of cancer screening developed by the World Health Organization [50] and the extensive experience in the EU in piloting and implementing population-based cancer screening programmes [46] . Screening is an important tool in cancer control in countries with a significant burden of CRC, provided the screening services are high quality [47] . The presently reported multidisciplinary, evidence-based guidelines for quality assurance in colorectal cancer screening and diagnosis have been developed by experts and published by the EU [37] . Methods ! The methods used are described in detail elsewhere in this supplement [29] . Briefly, a multidisciplinary group of authors and editors experienced in programme implementation and quality assurance in colorectal cancer screening and in guideline development collaborated with a literature group consisting of epidemiologists with special expertise in the field of CRC and in performing systematic literature reviews. The literature group systematically retrieved, evaluated and synthesized relevant publications according to defined clinical questions (modified Patient-Intervention-Comparison-Outcome-Study method). Bibliographic searches for most clinical questions were limited to the years 2000 to 2008 and were performed on Medline, and in many cases also on Embase and The Cochrane Library. Additional searches were conducted without date restrictions or starting before 2000 if the authors or editors who were experts in the field knew that there were relevant articles published before 2000. Articles of adequate quality recommended Multidisciplinary, evidence-based guidelines for quality assurance in colorectal cancer screening and diagnosis have been developed by experts in a project coordinated by the International Agency for Research on Cancer. The full guideline document covers the entire process of populationbased screening. It consists of 10 chapters and over 250 recommendations, graded according to the strength of the recommendation and the supporting evidence. The 450-page guidelines and the extensive evidence base have been published by the European Commission. The chapter on evaluation and interpretation of screening out-comes includes 20 graded recommendations. The content of the chapter is presented here to promote international discussion and collaboration by making the principles and standards recommended in the new EU Guidelines known to a wider professional and scientific community. Following these recommendations has the potential to enhance the control of colorectal cancer through improvement in the quality and effectiveness of the screening process, including multi-disciplinary diagnosis and management of the disease.
by authors because of their clinical relevance were also included. Only scientific publications in English, Italian, French and Spanish were included. Priority was given to recently published, systematic reviews or clinical guidelines. If systematic reviews of high methodological quality were retrieved, the search for primary studies was limited to those published after the last search date of the most recently published systematic review, i. e. if the systematic review had searched primary studies until February 2006, primary studies published after February 2006 were sought. If no systematic reviews were found, a search for primary studies published since 2000 was performed.
In selected cases references not identified by the above process were included in the evidence base, i. e. when authors of the chapters found relevant articles published after 2008 during the period when chapter manuscripts were drafted and revised prior to publication. The criteria for relevance were: articles concerning new and emerging technologies where the research grows rapidly, high-quality and updated systematic reviews, and large trials giving high contribution to the robustness of the results or allowing upgrading of the level of evidence. The methodological quality of the retrieved publications was assessed using the criteria obtained from published and validated check lists. Evidence tables were prepared for the selected studies. The evidence tables, clinical questions and bibliographic literature searches are documented elsewhere [28] . In the full guidelines document prepared by the authors and editors [37] over 250 recommendations were formulated according to the level of the evidence and the strength of the recommendation using the following grading scales.
Level of evidence I multiple randomised controlled trials (RCTs) of reasonable sample size, or systematic reviews (SRs) of RCTs II one RCT of reasonable sample size, or 3 or less RCTs with small sample size III prospective or retrospective cohort studies or SRs of cohort studies; diagnostic cross-sectional accuracy studies IV retrospective case-control studies or SRs of case-control studies, time-series analyses V case series; before/after studies without control group, cross-sectional surveys VI expert opinion
Strength of recommendation:
A intervention strongly recommended for all patients or targeted individuals B intervention recommended C intervention to be considered but with uncertainty about its impact D intervention not recommended E intervention strongly not recommended Some statements of advisory character considered to be good practice but not sufficiently important to warrant formal grading were included in the text. 
Results

3.1
The development of comprehensive systems for documentation of the screening processes, monitoring of data acquisition and quality, and accurate compilation and reporting of results are essential to the evaluation of population screening programmes (VI -A). Sect 
Introduction
Evaluation and interpretation of screening outcomes are essential to recognising whether a colorectal cancer screening programme is achieving the goals for which it has been established. It is recognised that the context and logistics of screening programmes will differ by country and even by region. For example, the prior existence of a population register facilitates issuing personalised invitations, whereas the absence of such a register may lead to recruitment by open invitation. Many of these contextual differences will affect the measured outcomes. The effectiveness of a programme is a function of the quality of its individual components. Success of the programme is measured not only by its impact on public health, but also by its organisation, implementation, and acceptability. The organisational aspects of a screening programme, described in Chapter 2 [26] of these Guidelines influence the evaluation and interpretation of screening outcomes. Therefore all aspects of the programme should be monitored and evaluated.
To determine whether a programme has been effective with regard to its impact on morbidity and mortality requires continuous follow-up of the target population over an extended timeframe. Therefore early-performance indicators using standard definitions, available early in the lifetime of a screening programme are essential to measure the quality of the programme and its potential longer-term impact.
A key component in the evaluation of population screening programmes is data collection. Colorectal cancer screening can be performed using various tests or techniques. Data collection necessary for evaluation can be common to all tests or specific to particular tests. The examples given in these Guidelines refer to in vitro stool tests based on detection of faecal occult blood (FOBT) that are currently the most widely used, and to endoscopic tests i. e. flexible sigmoidoscopy (FS) or colonoscopy (CS).
In the text, gFOBT refers to guaiac-based FOBTs, and iFOBT to immunological FOBTs. This chapter includes only the minimum data variables and indicators that should be collected and measured for the purposes of programme evaluation. It does not discuss quality indicators such as those used to measure endoscopist performance or patient satisfaction; a number of such indicators are described elsewhere in the Guidelines.
It should be noted that in a setting where opportunistic screening (for example by colonoscopy) has been taking place for some time, the uptake and performance of an organised programme may differ markedly from those in a setting where no such screening has been taking place. The majority of the values of the indicators described below will relate to the latter setting.
Recommendation ▶ The development of comprehensive systems for documentation of the screening processes, monitoring of data acquisition and quality, and accurate compilation and reporting of results are essential to the evaluation of a population screening programme [7] (VI -A). Rec 3.1
Data items necessary for evaluation
This section describes the data items and information that must be collected, recorded and stored in order to generate the indicators, analyses and reports required for evaluation.
Programme conditions
Programme type As mentioned above, the organisational aspects of a screening programme influence the evaluation and interpretation of screening outcomes. Population-based programmes are recommended because they require an infrastructure that is conducive to implementation of quality assurance and evaluation, such as through linkage of screening data and cancer registry data [47] . It is therefore important to document the type of programme (population-based or non-population-based) and to describe the sources of population data used for identification and invitation of the eligible target population (e. g. population registry). Data on screening outcomes should be linked with data from other registries in order to monitor and evaluate the programme.
Primary screening test
Currently only the faecal occult blood test (FOBT) is recommended by the EU for CRC screening. However endoscopic screening programmes with flexible sigmoidoscopy (FS) or colonoscopy (CS) as primary screening tests are currently running in a number of Member States. Given the potential impact of the type of primary screening test or tests used in a programme on the respective results and performance, the type of primary screening test should always be indicated when documenting results and reporting.
Population base
A screening programme is population based when every member of the target population in the area designated to be served by the programme is known to the programme, and when the eligible members of the target population are individually invited to participate. The availability and reliability of target population data will depend on the existence, quality and accessibility of population registers in the region where the programme is being set up. Population registers are not always available and demographic data for identifying the target population might be obtained from various sources, e. g. census data, electoral registers, private or statutory health care registers or health insurance funds registers. The choice of the target population database for issuing invitations will depend on the completeness of the database and on the individuals or variables included, e. g. electoral registers might not include eligible foreigners or dates of birth.
A database consisting of individual records (one record per person for each screening episode) is essential in order to produce results on organisational aspects of the programme (coverage, participation) and screening performance. This ensures maximal flexibility of the database for future evaluation efforts and participation in multi-centre studies. It also permits distinguishing between the first and subsequent screening episodes and between participants with different patterns of attendance (see Section 3.3).
▶ Self registrations
Self registrations are defined as eligible residents of the designated area served by the programme, who request screening but who are not identified by the target population register used to generate invitations. Their number should be reported separately.
▶ Self referrals
Self referrals are defined as people requesting screening before receipt of an invitation or outside the invited age-range. They should not be included in coverage by invitation, or in participation rate if in the relevant age range, but their number should be reported separately. 
Recommendations
Invitation variables
Target population
The target population are those people of eligible age according to the programme policy residing in the area designated to be served by the screening programme.
Eligible population
The eligible population are those people in the target population who fulfil the eligibility criteria specified in the programme policy.
Invited
The invited are those members of the eligible population who have received an invitation for screening according to the pro-gramme policy/process; e. g. invited by mail, by primary care practitioner. N.B. Not all invitations sent may be received.
Process variables of primary screening and follow up
Process variables in screening with the faecal occult blood test (FOBT) and other in vitro tests
The following process variables are described in the context of screening with faecal occult blood testing because FOBT is the only screening test currently recommended by the EU. In principle, the same definitions apply to other in vitro tests. It is recommended that the type of test used for screening is indicated when reporting data
The group of screened or tested participants are those who have used and returned an FOBT irrespective of the result. This includes people with inadequate/incomplete results. Note that each person is counted once regardless of the number of tests performed.
▶ Inadequate test
An inadequate FOBT is a test returned by a participant, the results of which cannot be reliably determined (see Chapter 4 [15] ). The quality is insufficient for processing and the test cannot be used for recording a result according to the programme policy.
▶ Positive test
A positive i. e. abnormal FOBT result is a result based on the last adequate test that according to the programme policy leads directly to referral to follow-up colonoscopy.
▶ Referral to follow-up colonoscopy 2
This variable refers to participants with a positive FOBT who require an appointment for follow-up colonoscopy. Ideally all participants with positive FOBTs would be referred to followup colonoscopy.
Variables in endoscopic screening
The following process variables are described in the context of CRC screening in which either flexible sigmoidoscopy (FS) or colonoscopy (CS) is used as the primary screening test.
▶ Screened
The group of screened participants comprises those people who have attended the FS or CS screening examination, irrespective of the result. This includes people with inadequate/ incomplete results. Note that each person is counted once regardless of the number of exams performed.
▶ Inadequate test
This group comprises those participants who attended the FS or CS screening examination, the results of which could not be interpreted because of inadequate preparation, and who do not have an adequate screening FS or CS in the reporting period. In such cases a new screening examination should be performed.
▶ Positive test
A positive i. e. abnormal screening FS or CS is one resulting either directly in diagnosis of cancer or removal of an adenoma or other lesion, or in referral for further investigation according to the programme policy (see Chapters 2 [26] and 5 [44] ).
▶ Referral to follow-up colonoscopy
Included in this group are the participants with a positive screening FS or CS who require a medical appointment for follow-up colonoscopy. 3 
▶ Referral to surgery or tertiary endoscopy
This group of participants includes those who require an appointment for surgery or tertiary endoscopy for removal of challenging lesions following a positive screening FS or CS (or as a consequence of follow-up colonoscopy after primary screening with FS or CS).
▶ Severe complications requiring hospitalisation
A very small number of participants will develop severe complications such as hospitalisation within 30 days due to serious haemorrhage involving transfusion, or due to perforation, vagal syndrome or peritonitis-like syndrome as a consequence of primary screening with FS or CS (or as a consequence of follow-up colonoscopy for any primary screening test).
▶ 30-day mortality
In a much smaller number of participants than those experiencing severe complications requiring hospitalisation, death may occur within 30 days after having undergone primary screening with FS or CS or follow-up colonoscopy, whether diagnostic or therapeutic, for any screening test. If the death is attributed to complications caused by the endoscopy, the participant should be counted in this group.
Programme outcome variables
The following outcome variables apply to CRC screening performed with any of the currently available primary screening tests.
Follow-up colonoscopy
Participants in the group on which diagnostic or therapeutic colonoscopy 4 has been performed to follow-up primary screening according to programme policy include participants, the screening endoscopy of which was inadequate or incomplete. Note that each person is counted once regardless of the number of followup colonoscopies that were performed. Where more than one colonoscopy or other follow-up investigation is performed, the reported result should be that of the complete diagnostic or therapeutic work-up. Definitions of what is included in the reported result (e. g. grade of neoplasia, 5 TNM stage, other lesions) are given in Chapter 7 [33] (Sect. 7.2, Table 7 .1, Rec. 7.1 -7.5, 7.8).
If more than one lesion is found, then the lesion with the worst prognosis (see Ch. 7 [33] ) should be indicated as the outcome of screening.
In the event of more than one detected lesion in a person where it is not possible to determine difference in prognosis, then the lesion requiring the most invasive procedure (see Ch. 7 [33] ) and Ch. 8 [41] ) should be recorded.
Lesions
Any lesion removed or biopsied at endoscopy or surgery (whether or not they were diagnosed as adenomas) should be recorded.
Adenomas
Pathological specimens removed at endoscopy or surgery, that have been reported by a pathologist to be adenomatous should be recorded.
Advanced adenoma
If it is not possible to collect such details for organisational reasons, the programme should at least focus on collecting and reporting data on adenomas ≥ 10 mm in size (see Ch. 9 [1] , Sect. 9.1). For definition, see Ch. 7 [33] , Sect. 7.2, and footnote 5 on previous page.
Cancers
Colorectal cancer diagnosed by the screening programme, or diagnosed as a direct result of participating in the screening programme (see Ch. 7 [33] , Sect 7.2 for definition). 
Severe complications requiring hospitalisation
Data tables
Recommendation ▶ For monitoring the programme, tables presenting performance indicators should be produced at regular intervals (at least annually) by age and gender and by type of screening test using the collected data (VI -A). Rec 3.5 Tables should present data for people, not data for tests, and therefore each person is counted once regardless of the number of tests performed (see• " Tab. 3.1). They should present the participation in the programme, the main results of testing, and the main detection outcomes. When processing the data, decisions should be made regarding age. Age can be calculated according to different events (age at invitation, age at time of screening, age at time of diagnosis). Age at time of screening is preferable for indicators pertaining to the testing procedure, results and outcome. Age should be presented in 5year groups.
Early performance indicators
Several rounds of screening are required before the impact of a screening programme on CRC mortality in the target population can be measured. Early performance indicators using standard definitions must therefore be used early in the lifetime of a screening programme to measure the quality of the screening process and to assess its potential longer-term impact. The accumulating experience in piloting and implementing populationbased screening programmes provides an evidence base that can be used to establish and refine standards and set performance targets.
Factors affecting performance indicators
Coverage and uptake, i. e. participation, are organisational parameters that apply to CRC screening programmes using any kind of primary screening test. They have a substantial impact on the potential effectiveness of any screening programme be- 3 In rare cases in which follow-up colonoscopy is not possible, other followup examinations may be performed. Those patients should be included in the group referred to follow-up CS but should also be counted separately. 4 See previous footnote on follow-up colonoscopy. 5 In screening programmes the use of the term "advanced adenoma" has developed and is sometimes used to categorise adenomas for management. In the present context an advanced adenoma is one that is either ≥ 10 mm or contains high-grade mucosal neoplasia or a villous component (Ch. 7 [33] ). cause they reflect the degree to which the population is exposed to the screening intervention. Coverage and uptake in turn will be affected by the age and gender distribution of the target population due to differential uptake rates. Screening performance indicators will be affected by the age and gender distribution of the population screened due to variation in underlying incidence of disease.
Recommendation ▶ All indicators should be calculated and reported for age-gender subgroups (VI -A). Rec 3.6 In addition, age-gender standardised measurements should be developed for comparative purposes. Age should be recorded as the age of the person at the time of the invitation (for measurement of coverage/participation) or at time of screening (for measurement of screening outcome) for the respective screening round. The outcome of the screening examination for a person should thus be recorded in the same age category throughout a particular screening episode. Screening performance indicators will also be affected by the background incidence in the target population in the absence of screening. Efforts should therefore be made to document agegender specific incidence rates in the target population for the period immediately prior to the introduction of the screening programme. If high-risk subjects are identified, managed, and/or excluded from the programme and reported separately, this should be stated. Performance indicators will also vary according to whether the screen is a prevalent (first) screen for those invited for the first time, an incident (repeat) screen for those previously screened at the routine interval, or a screen for previous non-responders. Indicators at subsequent rounds will vary according to the screening interval. Only the first organised screening round will consist entirely of subjects invited and attending for the first time; all additional rounds will comprise subjects falling into each of the categories described above. The cut-off point for separating 'subsequent regular' from 'subsequent irregular' screening should be estab-lished, taking into consideration that most programmes do not succeed in inviting each individual participant at the routine screening interval (e. g. a cut-off point at 30 months for a programme with a 2-year screening interval). Data should be analysed separately for those invited/screened at:
▶ initial screening, i. e. the first invitation of individual people within the screening programme, regardless of the organisational screening round;
▶ subsequent invitation for previous never responders; ▶ subsequent invitation for those previously screened 6 ; ▶ screens as a result of self-referral (defined as people requesting screening before reception of an invitation or outside the invited age range); and ▶ screened following self-registration (those not recorded in target population).
• " Tab. 3.2 -Tab. 3.5 list the key performance indicators for gFOBT, iFOBT, FS and colonoscopy respectively that have been reported from randomised controlled trials and from populationbased programmes. For the majority of indicators the published values will have been influenced by the screening policy adopted in the respective trials and programmes. Other than those related to participation, the values reported here have therefore not been used to define acceptable levels. There are a large number of possible process indicators, reflecting specific parts of the screening process. The present outline is confined to those that have epidemiological importance as identified within the trials. They measure participation, quality, efficacy, and organisation. Except for measures of participation, all other indicators are presented separately for in vitro tests (FOBT) and for endoscopic tests (FS or colonoscopy).
Programme coverage and uptake
Coverage and uptake, i. e. participation are organisational parameters that apply to CRC screening programmes using any kind of primary screening test.
Coverage by invitation
Coverage of the screening programme by invitation is the extent to which the invitations sent out by the screening programme within the defined screening interval include the eligible population. It gives information on the performance of the organisation of the programme in inviting the target population within the defined screening period. The eligible population is defined in Ch. 2 [26] , Sect. 2.3.1.1 (inclusion/exclusion criteria). in the case of yearly reporting. Recommendation ▶ Invitation coverage should be high (95 %) in order to maximise screening impact. (VI -A). Rec 3.7 Coverage by examination Coverage of the screening programme by examination is the extent to which screening examinations have actually been delivered to the eligible population. Screened here is defined as people tested at least once regardless of whether the result was adequate or inadequate and includes self referrals but not self registrations. The latter should be counted but reported separately. Coverage of the target age range for invitation will by definition exclude self referrals outside the age range. This is important in programmes where no comprehensive population lists are available and self referral or self registration can account for a large proportion of subjects screened. Both of the coverage indicators (by invitation and examination) are useful at a local level to assess completeness of population lists and target population's database. Positive FOBT rate In the RCTs of gFOBT, the positive rate without rehydration was 1. Positive test rates for gFOBT will depend on the method of slide handling used, and will be higher if the slides are rehydrated. The positive rate for iFOBT will vary according to the cut-off level adopted (see Chapter 4 [15] ). Positive rates should be presented in a table by 5year age groups and gender. Positive rates are higher in men than in women and increase with age in both genders reflecting the natural history of the disease. Recommendation ▶ A completion rate of follow-up colonoscopy of > 90 % is acceptable, > 95 % is desirable (see also Ch. 5 [44] , Rec. 5.41) (III -A). Rec 3.11 If more than one lesion is found, the lesion with the worst prognosis should be used for evaluation purposes as the result of follow-up colonoscopy. In the event of more than one detected lesion in a person where it is not possible to determine difference in prognosis, then the lesion requiring the most invasive procedure should be recorded, (see Ch. 1 [23] and Ch. 7 [33] ).
Detection rates of FOBT screening programme ▶ Lesion detection rate
The lesion detection rate is reported in % and is defined as the proportion of participants with at least one detected lesion among those adequately tested during the respective time frame.
N people with at least one detected lesion during the time frame* N people adequately tested during the time frame* * equal to the defined screening interval or reporting period ▶ Adenoma detection rate
The adenoma detection rate is reported per 1000 (‰) and is defined as the proportion of participants with at least one detected adenoma among those adequately tested during the respective time frame. The stage distribution of screen-detected cancers should be reported by screening round, age and gender. In the RCTs using only gFOBT, the proportion of screen-detected cancers that were Dukes Stage A ranged from 26 % to 36 % (• " Tab. 3.2).
The staging of colon cancer should use firstly the international TNM classification and secondly the Dukes classification (see Chapter 7 [33] ).
Recommendation
▶ A favourable stage distribution in screen-detected cancers compared to clinically diagnosed cancers should be observed. In absence of this condition a screening programme could not be effective (I -A). Rec 3.12 Positive predictive values for FOBT screening programmes Since lesions can only be detected if follow-up colonoscopy is performed, the definitions below take into account whether or not follow-up CS was actually performed. Other positive predictive values can be calculated, such as the PPV of the positive test without any further adjustment. In this case, the denominator would be the number of people presenting with a positive test result leading to referral for colonoscopy.
▶ PPV for detection of lesions
The positive predictive value (PPV) for detection of a lesion through an FOBT screening programme is defined as the percentage of people with detection of at least one lesion at follow-up CS among those with positive FOBT tests who have attended follow-up CS. 
Outcomes with flexible sigmoidoscopy (FS) or colonoscopy (CS) as primary screening tests
A table should be made to present the test results (positive, negative, or inadequate) by gender and age. Results should also be broken down by initial and subsequent screens as described above (Sect. 3.3).
Inadequate FS or CS rates
An inadequate FS or CS occurs when the examination cannot be performed because of inadequate preparation. In two RCTs inadequate FS rates ranged from 11 % to 12.7 % (• " Tab. 3.4) [40, 48] . Complete FS or CS rates FS and CS examinations are considered complete when conducted under adequate bowel preparation and with visualisation of the colon beyond the sigmoid-descending-colon-junction (FS), or the caecum (CS). One RCT has reported a rate of incomplete CS examination of 7.5 % [40] . Other authors reported rates of 1.3 % and 8.9 % for CS [34, 36] . The recommended standard (unadjusted caecal intubation rate, see Ch. 5 [44] , Sect 5.4.5.1) is > 90 %. A similar table should be made to present the endoscopic results of follow-up colonoscopy in participants with positive FS or CS screening exams who are referred to follow-up colonoscopy (see below).
To calculate the following detection rates, the data of the two tables should be combined. Separate analysis of screening and follow-up endoscopy is also recommended for quality assurance purposes (see below: "Follow-up colonoscopy outcome tables").
Positive FS or CS rate
The positive FS rate reported in different studies depends on the definition used (for example whether removed lesions not requiring further surveillance are recorded as a positive result or a negative result [24, 34, 36] . The latter rate was reported in a study with a high percentage of participants with a family history of CRC. The lesion detection rate is reported in % and is defined as the proportion of participants with at least one detected lesion among those adequately tested during the respective time frame. Detection rates should be presented in a table by 5-year age groups and gender. The adenoma detection rate is reported in % and is defined as the proportion of participants with at least one detected adenoma among those adequately tested during the respective time period. ▶ Advanced adenoma detection rate
The advanced adenoma detection rate is reported in % and is defined as the proportion of participants with at least one detected advanced adenoma among those adequately tested during the respective time period.
N people with at least one detected advanced adenoma during the time frame* N people adequately tested with FS or CS, respectively, during the time frame* * equal to the defined screening interval or reporting period Advanced adenoma detection rates of 4.9 % to 8.6 % have been reported in population studies of colonoscopy [24, 34, 36] (• " Tab. 3.5).
▶ Cancer detection rate
The cancer detection rate is determined as the proportion of FS or CS screening participants, respectively, with at least one detected colorectal cancer among those adequately examined during the respective time period. In the RCTs of flexible sigmoidoscopy, detection rates ranged from 2.9‰ to 5.4‰ (• " Tab. 3.4). Somewhat higher rates can be expected for screening CS due to inspection of the entire colon. As a percentage of all people with a positive test result, referral rates for follow-up colonoscopy will be much higher in FOBTbased screening programmes, than in FS screening programmes, depending on the programme policy for referral after a positive screening FS. Referral for follow-up CS after screening CS will be much less common than after screening FS because most lesions found at screening can be removed during screening CS. However, as a proportion of all people referred to follow-up according to the programme policy, compliance should be high irrespective of type of primary screening test. 
Recommendation
Completion of follow-up colonoscopy after FS or CS
The proportion of follow-up colonoscopies that are incomplete (lack of visualisation of the caecum, see Ch. 5 [44] , Sect. 5.4.5.1) should be recorded.
Recommendation
▶ For follow-up colonoscopy after FS or screening CS, a completion rate of 90 % is acceptable, > 95 % is desirable (see also Ch. 5 [44] , Rec. 5.41) (III -A). Rec 3.11 If more than one lesion is found during follow-up colonoscopy, then the lesion with the worst prognosis should be used for the programme evaluation.
In the event of more than one detected lesion in a person where it is not possible to determine difference in prognosis, then the lesion requiring the most invasive procedure should be used for the evaluation database (see Sect. 3.2.4; Ch. 7 [33] ).
Endoscopic complications of FS or CS screening programmes
The endoscopic complications that can appear in CRC screening programmes using FS or CS are the same as those described above with respect to follow-up colonoscopy performed in an FOBT screening programme (see Sect. 3.3.2).
The following complications are defined as serious: death within 30 days; or hospitalisation within 30 days due to serious haemorrhage involving transfusion, or due to perforation, vagal syndrome or peritonitis-like syndrome. All complications should be recorded as well as the respective cause, if discernible. For any complication the rate is defined as the proportion of participants presenting with a complication among those having atten- 
Screening organisation
A number of indicators can be used to monitor the organisational performance of a screening programme.
Time interval between completion of test and receipt of results
The time interval between performing a test and receipt of results will affect patient outcomes in terms of anxiety and potentially screening outcomes in terms of stage of diagnosis of disease.
Recommendation
▶ The time interval between completion of test and receipt of results by the subject should be as short as possible, (acceptable standard: > 90 % within 15 days) (VI -A). Rec 3.15 Time interval between positive test and follow-up colonoscopy A timely procedure is not critical in the context of primary screening but it is very important when endoscopy is performed following a previous positive screening test. A delayed procedure may not be critical biologically, but it can cause unnecessary anxiety for the screenee.
To ensure that patient anxiety is not unnecessarily increased, it is recommended that follow-up colonoscopy after positive screening be performed as soon as reasonably possible but no later than within 31 days of referral. VI -B) . Rec 3.16 Time interval between positive endoscopy (CS or FS) and start of definitive management The interval between the diagnosis of screen-detected disease and the start of definitive management is a time of anxiety for the patient and affords the opportunity, if prolonged, for disease progression. For these reasons, standards aimed at minimising delay have set the maximum interval at 31 days [31] 
Long-term impact indicators
The primary objective of screening for CRC is to achieve a reduction in disease-specific mortality; in the case of FS or colonoscopy screening this will be achieved largely by a reduction in the incidence of CRC. However such a reduction in either mortality or incidence will not be discernible until many years after the introduction of the screening programme. (In some areas, opportunistic screening by colonoscopy may be widespread before the start of the programme, therefore diluting the effect of a programme). Methods for studying mortality reduction are discussed later in this chapter. In the meantime other indicators of the impact of screening on disease incidence and mortality should be monitored. These include rates of interval cancers, and surrogate outcome measures that can be used to predict the impact of screening on CRC mortality (or on the incidence of invasive disease) such as rates of overall (age-specific) incidence, stage-specific incidence rates [8] .
Costs associated with all aspects of the programme should be recorded. Estimates of cost effectiveness will vary according to the health care system in the area. Costs should be monitored carefully, but comparisons between countries will be complex. (Aspects of cost-effectiveness are discussed in Chapter 1 [23] ). Finding the appropriate networking level for evaluation of incidence and mortality depends on the organisational structure of the programme. In some programmes (e. g. UK) this will be at a national level, whereas for others it will be at a regional level.
Recommendation
▶ Evaluation of surrogate outcome measures requires rigorous data collection of bowel cancer registrations and stage of disease in the target population. It is also preferable that such data are collected for the time period leading directly up to the introduction of a screening programme to allow trends to be analysed (VI -A). Rec 3.18
Interval cancers
Interval cancers are those that occur following a negative screening episode, in the interval before the next invitation to screening is due. For faecal occult blood testing interval cancers may occur following a negative FOBT, or following a positive test result with negative further assessment (colonoscopy). Rates of interval cancers reflect both the sensitivity of the screening test (false negatives), and the incidence of newly-arising cases not present at the time of screening. With increasing time since negative test, the rate and proportion of the latter will increase. In the absence of repeat screening, incidence rates would eventually reach the background level again. Rates of interval cancers should therefore be presented by time period (years) since previous screen. For endoscopy screening and for colonoscopy follow-up of FOBT, interval cancers reflect the quality of screening as well as the sensitivity of the screening test.
Recommendation
▶ Data on interval cancers should be collected and reported (VI -A). Rec 3.19 Recommendation ▶ Evaluation of interval cancer rates requires careful linkage of cancer registrations with screening history to allow cancers to be classified (i. e. as screen detected, interval, non-responders, other). The requisite linkage must be established with the cancer registry (VI -A). Rec 3.20 Rates of interval cancers will depend on the underlying incidence in the population. They will also depend on the extent of selection bias, whereby rates in those not participating in screening differ from the general population rates. For this reason it is important that (age-and gender-specific) incidence rates in non-responders are also monitored, to allow for the underlying incidence in responders to be estimated. Background incidence rates can be estimated from rates prior to the introduction of screening (although time trends need to be considered) or from areas not covered by the screening programme (when geographic differences need to be considered). The interval cancer rate can therefore be expressed as a proportion of the background incidence rate, standardised for age and gender, by dividing the number of interval cancers in the specific age/gender group (I) by the ones expected based on the background incidence for that age/gender group (C), or as a proportion of the background incidence rate adjusted for non-participants (C*). The adjusted rate can be calculated as: C* = (C -(1 -P) N) / P P: participation rate N: rate in non-responders The comparisons can be adjusted for differences in age and gender. The rate of interval cancers in the period after a negative screening provides information on the sensitivity of the programme. The sensitivity of gFOBT-based program for detection of cancer has been estimated as 55 % -57 % using this method. In the Nottingham trial the estimate was based on overall rates of interval cancers of 0.64 per 1000 person-years in the two year period after screening [30] . Using the same method, the sensitivity of iFOBT-based programme has been reported as 82 % [51] . No data are available yet on the sensitivity of FS or colonoscopybased programmes.
CRC incidence rates
Immediately following the introduction of a screening programme, incidence rates in the target age range should increase due to the detection of prevalent disease by screening. At rescreening, rates should return to background level apart from the advancement of the age of diagnosis by screening. Age-and gender-specific incidence rates should therefore be reported over time. FS screening should eventually lead to a reduction in incidence rates due to detection and removal of adenomas of the distal colon, but as discussed above this is a long-term effect. Screening FOBT may also have an eventual impact in reducing incidence rates, but the effect will be less due to lower detection rates of adenomas. Cumulative incidence rates or proxies should be used to monitor potential over-diagnosis of cancer, that is cancer that would not otherwise appear during the lifetime of the individual.
Rates of advanced-stage disease
Screening (both FOBT and FS) should result in a reduction in the overall population incidence of late stage disease (DUKES C & D) prior to any reduction in mortality and can therefore be used as an early indicator of effectiveness. Because screening will result in the detection of a large number of early stage cases, and hence a reduction in the proportion of late stage disease, it is preferable to monitor rates of late stage disease. The ability to do this will depend on the completeness of stage information that ideally should be available for a sufficiently lengthy period immediately prior to the introduction of the screening programme, to allow trends to be studied.
Projected mortality based on stage-adjusted cancer incidence. Models have been developed to use prognostic information provided by Dukes stage and age at diagnosis to predict cancer mortality.
CRC mortality rates
As discussed above, it will be several years before the impact of population screening on CRC mortality becomes observable, and many more years before the full effect is achieved. The timing of a reduction depends on the natural history of the disease, and the 'lead time' due to screening (i. e. the time by which screening advances the date of diagnosis) as well as on the time taken to cover the target population. It will also depend on the quality of screening. Methods to evaluate the impact of screening on CRC mortality include analyses of population trends, cohort studies (aggregated or individual-based) and case-control studies.
Population trends
Mortality from CRC has been decreasing in many European countries since the mid 1990's [20] . Analyses of the routinely produced age-gender specific population rates over time will be subject to limitations due to the dilution of the effect of screening from deaths occurring in cases diagnosed prior to the introduction of screening, and/or at an age below which invitations begin. This can be overcome by use of refined CRC mortality rates in which such deaths are excluded. However, the rates will also be confounded by other factors such as cohort effects on underlying incidence, and by the effects of improvements in treatment and/ or the stage of diagnosis of symptomatic disease on survival and mortality. Thus whilst a lack of any reduction in population mortality rates several years after the introduction of a screening pro-gramme should be a cause for concern, it is difficult to use such trends to quantify the effect, and attempts to do so should take account of the factors discussed above.
Cohort studies
In some settings, the introduction of population screening will have been phased in such a way as to facilitate comparisons of populations invited at different time points. Such a model has been used in Finland (see Ch. 2 [26] , Sect. 2.6.4). In the absence of such a system, comparisons can be made between geographical areas (regions invited/not invited to screening) or between the same population in different time periods before and after the introduction of screening. Both types of comparison are liable to possible bias due to underlying differences in the risk in the populations/time-periods. This mayunder certain circumstancesbe compensated for by including also a comparison group from geographic areas where no invitational program existed from before the introduction of screening. Cohort studies using aggregated data need estimates of incidence in order to avoid dilution effect discussed above. These biases can be avoided by individual-based cohort studies in which deaths and cancer registrations are linked to screening histories.
Case-control studies
Case control studies that compare 'exposure' (i. e. 'screening') between cases (deaths from CRC) and controls are an attractive alternative to cohort studies in terms of cost and effort. However, careful consideration of the design issues is necessary to avoid a number of potential biases [19] . The major problem with such studies is that of selection bias, due to different levels of underlying risk in participants and non-participants with screening. Methods to adjust for this are required both to estimate the mortality benefit in those actually screened, and the 'impact' on the population invited for screening.
Conclusions
!
In a multidisciplinary process, wide consensus has been achieved on a comprehensive package of evidence-based recommendations for quality assurance in evaluation and interpretation of outcomes in colorectal cancer screening. Following these recommendations has the potential to enhance the control of colorectal cancer in Europe and elsewhere through improvement in the quality and effectiveness of screening programmes and services.
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